Navigation Links
Newest cancer therapies multi-task to eliminate tumors
Date:9/16/2011

AUGUSTA, Ga. Some of the newest therapies in the war on cancer remove the brakes cancer puts on the immune system, Georgia Health Sciences University researchers report.

These immunotherapies, such as CTLA4, strengthen the immune system's attack on cancer by keeping apart two proteins that prevent key immune cells called T cells from activating.

Research featured on the cover of the Journal of Immunology suggests that these therapies also keep tumors from benefitting from IDO, an enzyme used by fetuses and tumors alike to suppress the immune response.

"This is an alternative way of avoiding the immune system brakes," said Dr. Andrew Mellor, Director of the GHSU Immunotherapy Center and the study's corresponding author. "These findings give us better insight into how cancer immunotherapy works so in the future we can better minimize the side effects and maximize the effect we want which is anti-tumor."

Mellor and Dr. David Munn, who leads the Cancer Immunotherapy Program in the GHSU Cancer Center and co-authored the study, led a research team that in 1998 identified IDO's role in preventing a mother's immune system from rejecting a fetus. They subsequently learned that tumors pirate the mechanism. The university has patented technologies to inhibit IDO, which are currently in clinical trials funded by the National Cancer Institute and corporate partners. "Tumors are really good at turning on IDO and after the cancer is found it becomes important to turn it off," Mellor said.

The study also provides new insight into cancer treatment vaccines that have worked well in the laboratory but are less successful in patients, Mellor said.

It suggests that the quantity of bacterial mimics, which get the attention of the immune system, is pivotal. Mellor and his colleagues showed in 2005 that the bacterial mimic CpG-ODNs can actually activate IDO. The new study confirmed that a lower dose avoided stimulating IDO while higher doses turned it on.

It also may help explain a common cancer vaccine side effect: the immune system's attack on healthy as well as cancerous tissue.

IDO, or indoleomine 2,3-dioxyegenase, locally suppresses immune system action by degrading tryptophan, an amino acid essential to survival of T-cells, orchestrators of immune response. Along with tumors, infectious agents, such as HIV, may use this mechanism to escape the immune system. In addition to pursuing the cancer treatment potential of IDO inhibitors, GHSU researchers have been looking at how invoking IDO can protect transplanted organs or treat autoimmune diseases such as rheumatoid arthritis and type 1 diabetes, respectively.


'/>"/>

Contact: Toni Baker
tbaker@georgiahealth.edu
706-721-4421
Georgia Health Sciences University
Source:Eurekalert  

Related medicine news :

1. Newest screen for newborns will indicate heart problems
2. AACR recognizes its newest grantees at 102nd Annual Meeting 2011
3. California Health Interview Survey releases newest data on state residents health
4. Not Just the Newest Toys Hold Risks for Kids
5. Throwdown, a Leader in Impact and Action Sports, Debuts Latest Innovations at the Newest UFC Gym™ in Rosemead, California
6. Pennsylvania's Newest Power Companies Right in Your Neighbor's Back Yard
7. Java Planet, Tampa Bay's Newest Organic Coffee Company Announces That it Has Become Fair Trade Certified™
8. InBoundMarketingPR: Cord Blood America Newest Inbound Marketing Client
9. Newest Release of FileTrail Sets New Standard in Global Physical Records Management and File Tracking
10. The Newest Concept in Knife Sharpening
11. Announcing the Newest and Most Anticipated Product of the Year: Coming Feb 24th
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newest cancer therapies multi-task to eliminate tumors
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
Breaking Medicine Technology: